Skip to main content
KALA
NASDAQ Life Sciences

KALA BIO Sets 1-for-30 Reverse Split, Trading Adjusted November 16

Tom Rudovsky · Reported by TMX Newsfile
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.149
Mkt Cap
$3.307M
52W Low
$0.115
52W High
$95.5
52W Position info
30% above low
Off High info
100% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

KALA sits 30% above its 52-week low of $0.115 on light trading volume (0.1× avg).

Summary

KALA BIO will execute a 1-for-30 reverse split effective 4:05 p.m. on November 13, 2026, with split-adjusted trading starting November 16 on the Nasdaq Capital Market under the same KALA symbol and a new CUSIP 483119400, while authorized shares stay unchanged at 1,500,000,000. The ratio sits inside the 1-for-2 to 1-for-300 range shareholders authorized at the November 3 special meeting, and it cuts outstanding shares from 19,339,786 to roughly 644,659. The board set the 1-for-30 ratio and approved the final certificate of amendment, which was filed with the Secretary of State of Delaware on November 12, 2026; the split applies to issued and outstanding shares and treasury stock alike, treats all stockholders uniformly without altering percentage interests except for fractional shares, and holders receive cash in lieu of fractional shares based on the November 12, 2026 closing price on the Nasdaq Capital Market. Outstanding equity awards, warrants and other convertible securities get proportional adjustments to share counts and exercise or conversion prices, and shares reserved under the 2017 Equity Plan and 2017 Stock Plan are proportionately reduced. This is the mechanical step to cure the Nasdaq delisting determination disclosed in the August 28 8-K after the stock spent 30 straight sessions below $1.00. The split fixes the bid-price problem but does nothing for the balance sheet: cash was under $0.1M at the last 10-Q, operations are being funded by loan collections, and the $15M ATM remains the dilution lever. Watch whether the post-split price holds above $1.00 through the compliance window Nasdaq grants.

Updated with an SEC 8-K filing · What changed

Updates

  1. · SEC 8-K — The key terms add that stock certificates for Old Common Stock will automatically represent the New Common Stock into which they were reclassified, without being presented for exchange, minus any fractional share.

    • Equity Award Adjustments — Proportional adjustments will be made to the number of shares issuable upon exercise or conversion of equity awards, warrants and other convertible securities, and to the applicable exercise or conversion price, including awards under the 2009 plan and the 2017 plans.
    • Plan Share Reduction — The number of shares reserved for issuance under the 2017 Equity Plan and 2017 Stock Plan is proportionately reduced in accordance with the terms of those plans.
    • Fractional Shares — Holders will receive a cash payment in lieu of fractional shares based on the closing price on the Nasdaq Capital Market on November 12, 2026; the split treats all stockholders uniformly and does not alter percentage interests except for fractional shares.
    • Certificate Filing
      • Certificate of Amendment filed with the Secretary of State of Delaware on November 12, 2026.
      • Board determined the Reverse Stock Split ratio of 1-for-30 and approved the corresponding final form of the Certificate of Amendment.
    • Share Scope — The split applies to shares issued and outstanding or held as treasury stock; any certificate for Old Common Stock will automatically, without being presented for exchange, represent the New Common Stock into which it was reclassified minus any fractional share.
    All 10 details
    • Proportionate adjustments to per share exercise price and number of shares purchasable upon exercise or conversion of outstanding equity awards under the 2009 Employee, Director and Consultant Equity Incentive Plan, Amended and Restated 2017 Equity Incentive Plan and Amended and Restated 2017 Employee Stock Purchase Plan.
    • Number of shares reserved for issuance under the 2017 Equity Plan and 2017 Stock Plan proportionately reduced in accordance with the terms of such plans.
    • Proportional adjustments to number of shares issuable upon exercise or conversion of equity awards, warrants and other convertible securities, and the applicable exercise or conversion price thereof.
    • Cash payment in lieu of fractional shares based on the closing price on the Nasdaq Capital Market on November 12, 2026.
    • Certificate of Amendment filed with the Secretary of State of Delaware on November 12, 2026.
    • Board determined the Reverse Stock Split ratio of 1-for-30 and approved the corresponding final form of the Certificate of Amendment.
    • The reverse stock split affects all stockholders uniformly and does not alter any stockholder's percentage interest in the Company's equity, except to the extent it would result in a stockholder owning a fractional share.
    • Proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion of the Company's equity awards, warrants and other convertible securities, as well as the applicable exercise or conversion price thereof.
    • The reverse split applies to shares of Common Stock either issued and outstanding or held by the Company as treasury stock.
    • Any stock certificate representing Old Common Stock immediately prior to the Effective Time automatically, without presenting it for exchange, represents the New Common Stock shares into which it was reclassified minus any fractional share.

At the time of this announcement, KALA was trading at $0.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.11 to $95.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.


Price Chart

Share this article

Copied!

KALA - Latest Insights

KALA
Nov 09, 2026, 8:00 AM EST
Source: TMX Newsfile
Importance Score:
7
Price at Filing: $0.1568
Real-time Price: $0.141 info
Change: Reverse Stock Split info
Market Cap: $3.114M info
KALA
Sep 29, 2026, 7:30 AM EDT
Source: TMX Newsfile
Importance Score:
8
Price at Filing: $0.474
Real-time Price: $0.141 info
Change: Reverse Stock Split info
Market Cap: $3.114M info
KALA
Sep 24, 2026, 4:10 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.5288
Real-time Price: $0.141 info
Change: Reverse Stock Split info
Market Cap: $3.114M info
KALA
Sep 11, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.590
Real-time Price: $0.141 info
Change: Reverse Stock Split info
Market Cap: $3.114M info
KALA
Sep 03, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.538
Real-time Price: $0.141 info
Change: Reverse Stock Split info
Market Cap: $3.114M info